2022

FEB, 10-11 PST
FEB, 11-12 KST

e Symposium

SAN FRANCISCO

KASBP
SAN FRANCISCO

Sponsors


Hanmi
Global · R&D Leader
Hanmi Pharm.


GC Cell


Keit


YUHAN


Therapeutics


KANAPH
Therapeutics Inc.


ablbio
medicine for a better life


samyang
Holdings


PharmAbcine
Antibody Therapeutics for Life


GENEDIT
GENE THERAPY DELIVERED


Cyrus
Therapeutics

KASBP-SF 2022 eSymposium (Feb 10 – 11, 2022)

Pacific time	**Feb 10, 2022 (Thursday)**
5:00-5:15 pm	**Opening and Congratulatory Remarks** ● Opening Remark, *Sehyun Kim (KASBP-SF President, ABL Bio)* ● Congratulatory Remark, *Hanjo Lim (KASBP President, Genentech)*
5:15 – 7:15	**Session 1: Drug Discovery & Development** *Moderator: Meena Choi (KASBP-SF Career Development Director, Genentech)*
5:15 – 5:55	MS-GF+ and Strelka2: contribution of algorithms to genomics and proteomics *Sangtae Kim (Bertis Bioscience)*
5:55 – 6:35	Use of Real-World Evidence (RWE) for FDA approvals *Youn Jeong (YJ) Choi (Genentech)*
6:35 – 7:15	The Use of Computer-Aided Modeling to Diagnose and Fix Tablet Compression Issues *John Austin (Gilead Sciences)*
7:15 – 7:25	**Break**
7:25 – 8:10	**Sponsor Presentation I** *Moderator: Dongkyoon Kim (KASBP-SF Science Director, Atreca)*
7:25 – 7:40	GC Cell *(Yu-Kyeong Hwang, Senior Vice President, Head of R&D)*
7:40 – 7:55	Samyang Holdings *(Helen Cho, Director of R&D)*
7:55 - 8:10	KEIT 한국산업기술평가관리원 *(Hyung Chul Kim, Bio Program Director)*
8:10 – 9:00	**Networking & Career Session** *Moderator: Sehyun Kim (KASBP-SF President, ABL Bio)*
	A: Business/Operations, *Moderator: Sehyun Kim (ABL Bio)*
	B: Oncology, *Moderator: Jihoon Chang (Kanaph)*
	C: Non-oncology, *Moderator: Hyunsun Jo (PIN Therapeutics)*
	D: Data Science, *Moderator: Meena Choi (Genentech)*
	E: Med Chem, *Moderator: Sunghoon Ma (Exelixis)*
	F: Career Development, *Moderator: Narae Lee (Arcturus Therapeutics)*

KASBP-SF 2022 eSymposium (Feb 10 – 11, 2022)

Pacific time	**Feb 11, 2022 (Friday)**
5:00 – 6:40	**Session 2: Business Development** Moderator: Sehyun Kim *(KASBP-SF President, ABL Bio)*
5:00 - 5:20	Business Development & Licensing at Merck *Koji Yashiro (Merck)*
5:20 - 5:40	Advancing the healthcare innovation and ecosystem building in Korea *Stephen Lee (J&J Innovation)*
5:40 - 6:40	Panel Discussion: *Koji Yashiro (Merck), Stephen Lee (J&J Innovation), Lauren Young-Mi Lee (Hanmi), Elizabeth Wu (J&J) and Grace Han McMahon (Merck)*
6:40 – 7:25	**Sponsor Presentation II I** *Moderator: Dongkyoon Kim (KASBP-SF Science Director, Atreca)*
6:40 - 6:55	Yuhan Corporation *(Han Kim, Head, Global Business Development)*
6:55 - 7:10	Kanaph Therapeutics *(Wonjae Lee, Business Development Associate)*
7:10 - 7:25	ABL Bio *(Sehyun Kim, Director, Open Innovation and BD)*
7:25 – 7:35	**Break**
7:35 – 8:50	**Session 3: Innovative Start-Ups** *Moderator: Ki Eun Pyo (KASBP-SF Membership Director, Medic Life Sciences)*
7:35 – 8:00	If you can imagine it, a microbe already does it: Finding powerful new microbes for the next generation of agricultural products *Barry Goldman (Pluton Biosciences)*
8:00 – 8:25	Innovations in Stem Cell Transplant *Jeet Mahal (Jasper Therapeutics)*
8:25 – 8:50	Molecular glue degrader as a new therapeutic modality *Hyunsun Jo (Pin Therapeutics)*
8:50 – 9:00	**Closing Remarks (or Q&A of Session 3)**

Session 1: SPEAKER

Sangtae Kim, Ph.D.
Bertis Bioscience, Chief Technology Officer

Bio-sketch

- Dr. Sangtae Kim is the Chief Technology Officer at Bertis Bioscience who lead the company's R&D and innovation in product development. Prior to his current position, he was principal scientist at Seer, staff bioinformatics scientist at Illumina and senior research scientist at Pacific Northwest National Laboratory.
- Dr. Kim has dedicated his career to developing innovative algorithms and software for high-throughput biological data analysis, ranging from genomic variant calling via next-generation sequencing to protein identification via mass spectrometry. He is well known in the scientific community as the developer of the widely-used software tools MS-GF+ and Strelka2. He has authored over 25 research papers and his publications current report over 4000 citations.
- Dr. Kim received B.S. and M.S. from Seoul National University, and Ph.D. from University of California, San Diego, all in computer science.

Abstract

Proteomics and proteogenomics (the integration of proteomics with genomics and transcriptomics) are becoming increasing popular in basic, translational, and clinical research. For the success of proteomics and proteogenomics research, computational tools that effectively and efficiently mine information from large omics data are crucial. In this talk, I will give an overview of basic concepts of interpreting mass spectrometry and next-generation sequencing data and share my experience in developing two software tools, MS-GF+ for peptide identification and Strelka2 for genomic variant calling. Particularly, I will explain how a dynamic programming algorithm enabled unbiased estimation of statistical significance of peptide identification, how an efficient tiered haplotype model improved genomic variant calling accuracy and, and how a joint somatic probability model improved robustness in somatic variant calling for liquid and late-stage tumor analysis.

Session 1: SPEAKER

Youn Jeong (YJ) Choi, Ph.D.
Genentech, Senior Principal Statistical Scientist

Bio-sketch

- Data Sciences Team Lead for Pediatric Oncology, Roche/Genentech (current)
- Hematology Biostatistics Liaison for External Controls, Roche/Genentech (current)
- M.S, and Ph.D in Statistics, University of Wisconsin - Madison

Abstract

Is real-world data (RWD) useful for regulatory approvals of new drugs? What does it mean that the FDA "used" RWE in the NDA and BLA process? What do the RWD components look like that are being submitted to FDA, as part of New Drug Applications (NDAs) and Biologic License Applications (BLAs)? The aim of this presentation is to provide a brief overview of recent and old FDA approvals involving RWE across different therapeutic areas, with specific interest in Oncology.

Session 1: SPEAKER

John Austin, Ph.D.
Gilead Sciences, Senior Scientist

Bio-sketch

- PhD in Chemical Engineering from Purdue University focusing on the development of novel electromagnetic sensors for pharmaceutical applications
- 8 years at Gilead Sciences. First 5 years in formulation and product development group. Most recent 3 years in Clinical Data Sciences.
- Currently focuses on database design, data visualization, and applying machine/deep learning techniques to uncover insights and develop new capabilities to improve patient lives.

Abstract

Tablet defects can occur seemingly at random and may be challenging to reproduce and even more challenging to diagnose. This is true in large part because tablet compression occurs in a fraction of a second in an opaque, sealed environment. Moreover, the formation of defects during tablet compression is also highly dependent on materials used and processing scale/parameters.
We apply finite element modeling using the modified Drucker-Prager/Cap material model to simulate tablet compression and to diagnose the formation of defects only observed during two production-scale runs. We also present lessons learned to help others better understand the impact of die shape on stresses during tablet compression.

Session 2: SPEAKER

Koji Yashiro, Ph.D.
Merck, Director of Pacific BD&L

Bio-sketch

- 1994~2002: Started industry carrier in a biotechnology division of HIGETA Soy Source Company in Japan developing recombinant protein expression systems.
- 2003~2008: Obtained PhD at the Department of Cell and Molecular Physiology in University of North Carolina at Chapel Hill publishing in top journals including Nature Neuroscience.
- 2008~2016: Led multiple drug discovery programs and created multiple collaborations with external parties at the research labs at Astellas.
- 2016~2020: Set up collaborations with Japanese universities and biotech companies and managed them as a senior alliance manager at Bayer.
- 2020~current : Scouting new assets in all therapeutic areas in Asia Pacific region as a director of Pacific BD&L at Merck.

Abstract

Merck has a strong history of success in translating cutting-edge research into life-saving medical breakthroughs. From Merck's development of the first measles and mumps vaccines to treatments for cancer and diabetes, we are an industry leader in bringing forth innovative new medicines. We operate in more than 140 countries and had sales of more than $48 billion in 2020.

We recognize that building partnerships is one of our most important jobs. In 2020, over 65% of our human health revenue was attributable to acquisitions, alliance partnerships and patents and our team executed more than 100 significant business development transactions. We have BD professionals based in key innovation epicenters including Boston, San Francisco, London, Shanghai, Tokyo and our headquarters in Kenilworth, NJ. **We are increasingly recognizing Republic of Korea as a center of new innovations as represented by our recent deals with Medpacto, Hanmi, Artiva/Green Cross, and Qurient.**

We're pursuing the most innovative areas in biomedical research emerging today without regard to therapeutic area or modality and working on collaborations from discovery to clinical-stage programs. We believe that by working together we can play a major role in transforming global health care. Together we can invent for life.

Session 2: SPEAKER

Stephen Lee, Ph.D., MBA
Director, Early Innovation Partnering, North Asia

Bio-sketch

- J&J Innovation, Asia Pacific Innovation Center (APIC), Director, New Ventures, North Asia
- Kybora EM (formerly Torreya EM), MD, APAC
- Ventac Partners, Partner, APAC
- USPTO, Patent Examiner

Abstract

For more than 130 years, the Johnson & Johnson Family of Companies has been combining heart, science and ingenuity to profoundly change the trajectory of health for humanity. Johnson & Johnson maintains an open, humble, and inclusive attitude towards innovation. The current innovation and development are no longer confined to a specific country or region. A good idea can come from anywhere. Our task is to find these innovators and forge the partnership collaborations with the pharmaceutical, medical devices, and consumer health sectors to accelerate the innovation that can truely benefit patients and consumers.

Through our global Johnson & Johnson Innovation network, we provide regional points of entry for life science and health technology innovators to access the breadth and depth of offerings that are unique to the Johnson & Johnson Family of Companies. By connecting the best science, technology and entrepreneurs to our resources, tools and expertise, we aim to expand and accelerate solutions that address the toughest healthcare challenges and improve the lives of patients and consumers around the world.

Session 2: PANEL

Lauren Young-Mi Lee, Ph.D.
Hanmi Pharm., SVP, Head of Global R&D Innovation, R&BD

Education & Experience:

1) Education
- BS, Ewha Women's University, College of Pharmacy
- MS & Ph.D, Seoul National University, College of Pharmacy (Pharmacokinetics & Hepatic drug transporters)

2) Experience
- present: Hanmi Pharm, SVP, Head of Global R&D Innovation, R&BD
- Hanmi Pharm, Vice President, Head of Global Business & Strategy
- Hanmi Pharm, Executive Director, Head of Biology & Translational Research
- Harvard Medical School, Department of Pathology/Dana-Farber Cancer Institute, Department of Cancer Biology, Boston, MA, Research Fellow
- German Cancer Research Center (DKFZ), Division of Tumor Biochemistry, Heidelberg, Germany, Visiting Researcher
- Dong-A Pharmaceutical Company, Central Research Center / Researcher

Profile

Dr. Lee leads Hanmi's Global R&D Innovation division which focuses on innovative global partnership with Oncology & Immunotherapy and novel Platform based breakthrough therapy. Meanwhile, she seeks cutting edge science and innovative disease targets, drug candidates as well as technologies with global collaborations.

It has been 10 years since she joined Hanmi, she worked as Head of Biology and Translational Research and Head of Global Strategy & Business Development. Before joining Hanmi, Dr. Lee focused her research at Dana-Farber Cancer Institute, Department of Cancer biology/ Harvard Medical School, on breast cancer stem cell, genome-kinases library development for new drug targets with synthetic lethality and cell cycle inhibitors. She was a faculty member at Yonsei University, Department of Biotechnology and Translational Research Center for Protein Function Control and worked at Dong-A Pharm Research Center. She received her Ph. Degree at Seoul National University, School of Pharmacy on Drug transporters and Pharmacokinetics.

Session 2: PANEL

Elizabeth C. Wu, Ph.D.
JNJ, Director, Early Innovation and Partnering

Bio-sketch

Liz is Director, Early Innovation Partnering at Johnson & Johnson Innovation, California. In this role, she focuses on pharmaceutical innovation in support of the immunology and cardiovascular & metabolism businesses. Her charge is to identify licensing, collaboration, and investment opportunities highly aligned with Johnson & Johnson business strategies by building relationships with entrepreneurs, venture investors, and key opinion leaders to secure early-stage external opportunities.
Previously, Liz held the role of Associate, Venture Investment with Johnson & Johnson Innovation – JJDC, Inc. where she was on global assignment in Seoul, South Korea. In this capacity, Liz played a critical role initiating and managing equity investments to drive business innovation and deliver new and sustainable business for the Consumer and Pharma sectors. She worked closely with the JJDC investment team where she was responsible for sourcing, analysing, evaluating, aligning, managing, exiting, and on-boarding investments in target companies.
Before joining Johnson & Johnson Innovation in 2015, Liz held positions of increasing responsibility at L'Oréal, including Associate Principal Scientist at L'Oréal Research & Innovation. Liz led the evaluation and established external collaborations in line with L'Oréal's R&D strategy on topics ranging from skin tissue engineering and bioprinting to non-invasive clinical tools. Through her efforts, she executed a number of external collaborations, several of which successfully achieved key scientific milestones.
Liz completed her Postdoctoral Fellowship at the Institute of Bioengineering and Nanotechnology, a member of A*STAR's biomedical sciences institutes in Singapore. Her work focused on the development and characterization of self-assembling peptide hydrogels, working to improve stability and demonstrate their capabilities to support cell proliferation. Liz earned her M.S. and Ph.D. in Bioengineering from University of California, San Diego, where her research focused on the development of biomaterials for the sustained delivery of therapeutics for retinal diseases and she received her B.S. in Bioengineering from University of California, Berkeley.

Session 2: PANEL

Grace Han McMahon, Ph.D.
AVP and Head, Pacific BD&L, Merck

Bio-sketch

Grace Han McMahon leads Merck's Pacific BD&L Hub whose remit is to identify, evaluate and transact on early-stage, transformative science with companies based in California, the Pacific Northwest and Asia. Prior to re-joining Merck in 2018, Grace worked for Genentech for five years where she lead a transactional team of attorneys responsible for negotiating licensing, collaboration and M&A deals. Grace started her career in the biopharma industry at Merck headquarters in the Office of General Counsel and prior to that worked in Paris, Boston and New York. Grace serves on the Board of California Life Sciences and is passionate about innovation, team building, diversity and baseball. Grace holds an M.B.A. from INSEAD, a J.D. from New York University School of Law and a B.A. from the University of Virginia.

Session 3: SPEAKER

Barry Goldman, Ph.D.
Pluton Bio, Founder and CSO

Bio-sketch

- PhD Microbiology
- Post-doc Biochemistry and Computational Biology
- Monsanto Company Led teams in Data Science, Tech Scouting, and Microbiology
- Indigo Ag Built Microbiome Research Pipeline
- Pluton Bio Founder and CSO

Abstract

By 2050 agriculture will need to feed 2 billion more people while having 15% less arable land. In addition, Climate Change caused by the increase in greenhouse gases is decreasing crop yields by 5-10% for every 1° increase in temperature. To address these problems, we need every solution possible. To the rescue come microbes. There are over a trillion species of microbes, yet as humans we have identified the value of only a tiny fraction of these organisms. Yet this tiny fraction has enabled life changing medicines, improved agriculture, and introduced life changing technologies such as PCR and CRISPR. At Pluton, we are working to find and harness the next generation of novel microbes to address the great challenges facing humanity. Our first product, we call a Microbial Cover Crop™ (MCC), is a novel combination of microbes that remove CO2 from the atmosphere and improve soil health. When applied to the hundreds of millions of acres of crops, our MCC will have a dramatic impact on the volume of greenhouse gases, impacting climate change.

Session 3: SPEAKER

Jeet Mahal
Jasper Therapeutics, Chief Financial and Business Officer

Bio-sketch

Mr. Mahal joined Jasper Therapeutics as Chief Financial and Business Officer from Portola Pharmaceuticals, where he worked for 11 years and held a number of positions of increasing leadership, most recently as Vice President, Business Development and Vice President, Strategic Marketing. He led the successful execution of multiple business development partnerships for Andexxa®, Bevyxxa® and cerdulatinib. He also played a key role in the company's equity financings, including its initial public offering and multiple royalty transactions. Earlier in his career, he was Director, Business and New Product Development, at Johnson & Johnson on the Xarelto® development and strategic marketing team. He started his career in the drug development laboratories at COR Therapeutics.

Abstract

Recent innovations in Stem Cell Transplant Technologies have the potential to significantly expand the use of this curative therapy across multiple inherited and acquired diseases such as Sickle Cell Disease, Severe Combined Immunodeficiency and Acute Myeloid Leukemia

Session 3: SPEAKER

Hyunsun Jo, Ph.D.
Pin Therapeutics, Founder and Chief Executive Officer

Bio-sketch

Dr. Hyunsun Jo is an entrepreneur in the biopharmaceutical industry. He is currently a Founder and Chief Executive Officer at Pin Therapeutics, which is located in South San Francisco and South Korea. Pin Therapeutics is backed by many venture capitals in South Korea and actively developing integrative drug discovery platform at the field of protein degradation therapeutics using small molecules. Prior to founding Pin Therapeutics, Dr. Jo has founded two biotech companies called by a LabQnA and an Embedbio. He obtained his BA and PhD in Molecular Biology (Metabolic Diseases) at Seoul National University and Postdoc (aging-related diseases) at the Gladstone Institute (UCSF).

Abstract

How to effectively find molecular glue degrader (MGD) is of interest from many companies. We aim to improve the efficiency of finding MGD by developing various assays. We make a rationale library using a binder (small molecule) that binds to E3 ligase and are actively conducting research to find new MGD through phenotypic screening and biophysical ternary assays.

KASBP-SF Committee

Sehyun Kim	President	ABL Bio
Gayoung Jeong	1st Vice President	Genentech
Oh Kyu Yoon	2nd Vice President	Gilead
Dongkyoon Kim	Science Director	Atreca
Joon Won Jeong	Finance Director	Exelixis
Joonhee Park	Public Relations Director	Amgen
Meena Choi	Career Development Director	Genentech
Ki Eun Pyo	Membership Director	Medic Life Sciences
Sunghoon Ma	Councilor	Exelixis
Hanjo Lim	Councilor	Genentech